Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Key news in Waldenström’s macroglobulinemia

Steven Treon • 15 Jun 2019
EHA 2019
Rare Diseases Waldenström’s Macroglobulinemia

Here, Steven Treon, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, discusses the key news in Waldenström’s macroglobulinemia from the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Steven Treon

How do tumor subclones and T-cell dynamics influence ibrutinib responses in Waldenström’s?
2:23
How do tumor subclones and T-cell dynamics influence ibrutinib responses in Waldenström’s?
Steven Treon • 14 May 2026
How do the clinicopathological features of IgM-MM and WM differ?
1:12
How do the clinicopathological features of IgM-MM and WM differ?
Steven Treon • 14 May 2026
The current status of bispecifics and CAR-T in Waldenström’s macroglobulinemia
2:01
The current status of bispecifics and CAR-T in Waldenström’s macroglobulinemia
Steven Treon • 14 May 2026
The role of BTK inhibitors in the current treatment landscape for WM
2:32
The role of BTK inhibitors in the current treatment landscape for WM
Steven Treon • 14 May 2026

Related Videos

Biomarker-driven prediction of ibrutinib response in Waldenström macroglobulinemia
1:04
Biomarker-driven prediction of ibrutinib response in Waldenström macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Single-cell and proteomic data to predict ibrutinib response in Waldenström macroglobulinemia
1:33
Single-cell and proteomic data to predict ibrutinib response in Waldenström macroglobulinemia
Tina Bagratuni • 23 Sep 2026
CTCs and plasma MYD88 VAF as liquid biopsy markers in Waldenström macroglobulinemia
1:52
CTCs and plasma MYD88 VAF as liquid biopsy markers in Waldenström macroglobulinemia
Tina Bagratuni • 23 Sep 2026
A new era for BCMA-targeted bispecific antibodies in AL amyloidosis?
1:49
A new era for BCMA-targeted bispecific antibodies in AL amyloidosis?
Giada Bianchi • 10 Sep 2026
The content of VJHemOnc is intended for healthcare professionals